The Eledon clinical trials focus primarily on evaluating the therapeutic efficacy and safety of tegoprubart, an anti-CD40 ligand antibody being investigated for use in organ transplantation—such as xenotransplantation and kidney transplants—as well as severe autoimmune diseases. These multi-center clinical studies aim to prevent organ rejection while minimizing the severe toxicities and adverse side effects commonly associated with legacy immunosuppressive drug regimens utilized in transplant patients.